Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Scientific Advisors

Founder, Founding Scientist, and Chair of Scientific Advisory Board (SAB)

Waldemar Priebe is a Founder of and a Founding Scientist at Moleculin and serves as head of our Scientific Advisory Board. Dr. Priebe is also a Professor of Medicinal Chemistry at the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Priebe led the discovery of the molecules that form the basis for our lead drug candidates.

As a Founder or Founding Scientist at a number of successful biotechnology firms such as Aronex Pharmaceuticals, Houston Pharmaceuticals, Reata Pharmaceuticals, and IntertechBio, Dr. Priebe has been integral in advancing several drugs through the pipeline, three of which are currently in clinical development. He has also developed several new small molecule compounds that have been licensed as potential drugs.

Madeleine Duvic is Professor of Internal Medicine and Dermatology and Deputy Chairman of the Department of Dermatology at MD Anderson, a former board member of the American Academy of Dermatology and recent Vice President of the Society for Investigative Dermatology. Elected to the ADA, Dr. Duvic is also a Founder and board member of the United States Consortium for Cutaneous Lymphomas, performs translation research in CTCL, and has been engaged in the design and conduct of clinical trials that resulted in new therapies for CTCL. Dr. Duvic also serves on Medical and Scientific Boards of the National Alopecia Areata Foundation and Cutaneous Lymphoma Foundation. She is the Principal Investigator of the NAAF funded Alopecia Areata Registry.

Consultant, Strategist, and SAB Member

Howard Maibach is considered a foremost consultant to the dermatology industry worldwide for large pharmaceutical companies and medium to small biotech companies. He has been a Professor in the Department of Dermatology at the U.C. San Francisco School of Medicine for over 35 years.

Dr. Maibach has served on editorial boards of 30 dermatology journals, authored over 2,500 peer-reviewed scientific articles and was the author or editor of 79 books including several classic textbooks used by dermatologists worldwide.


Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates regarding Moleculin and breakthrough Cancer related innovations!

You have Successfully Subscribed!